SLC7A5 and metastatic malignant neoplasm: Metastatic cancers, and particularly BrM, express high levels of LAT1 [17]; triple negative breast cancer (TNBC), has high levels of LAT1 expression [18], high risk of BrM including LMD, and generally lacks targeted treatment options [18].